May 25, 2018
Lawrence Toll, Ph.D., expected to describe company’s novel opioid that shows no signs of addiction potential May 24, 2018 07:00 AM Mountain Daylight Time SALT LAKE CITY–(BUSINESS WIRE)–Phoenix PharmaLabs, Inc. (“Phoenix”), a privately held company developing a novel opioid that Read more…
